Basic Science Award recipient Alberto Ouro, PhD, presented his team’s cross-sectional study at the American Headache Society 68th Annual Scientific Meeting in Orlando, FL. The award recognizes the top basic...
A 1-year interim analysis of a phase 3, multicenter, open-label, 156-week extension study found overall reductions in systolic and diastolic blood pressure with atogepant 60 mg once daily in persons with...
In an Early Career Lecture Award study presented at the American Headache Society 68th Annual Scientific Meeting, nitroglycerin provoked headache and vestibular symptoms in participants with definite...
At the American Headache Society 68th Annual Scientific Meeting, Yaseen Agbaria, PhD, received the Harold G. Wolff Lecture Award for the best new paper on headache or facial pain. In their paper, Agbaria...
In a post-hoc analysis of a phase 3, open-label, 52-week LTE trial presented at the American Headache Society 68th Annual Scientific Meeting in Orlando, FL., ubrogepant 100 mg showed consistent 2-hour pain...
At the 2026 American Academy of Neurology Annual Meeting in Chicago, IL, investigators presented real-world evidence evaluating whether glucagon-like peptide-1 receptor agonists influence healthcare...
Several sessions at the 2026 American Association of Nurse Practitioners National Conference in Las Vegas, NV, will address migraine-related diagnosis, treatment, red flags, and care considerations across...
Physicians managing chronic migraine may be interested in new comparative patient-reported data from the FORWARD study, which evaluated treatment satisfaction with onabotulinumtoxinA versus topiramate. In...
